Adamo MDL, Ruhl J (2015) National Cancer Institute SEER Coding and Staging Manual 2015. . National Cancer Institute: Bethesda, MD, USA, pp 20850–29765.
Aguilo R, Macia F, Porta M, Casamitjana M, Minguella J, Novoa AM (2008) Multiple independent primary cancers do not adversely affect survival of the lung cancer patient. Eur J Cardiothoracic Surg 34(5): 1075–1080.
Ahn DH, Mehta N, Yorio JT, Xie Y, Yan J, Gerber DE (2013) Influence of medical comorbidities on the presentation and outcomes of Stage I-III non-small-cell lung cancer. Clin Lung Cancer 14: 644–650.
Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, BKe Edwards (eds) (2010) SEER Cancer Statistics Review, 1975–2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2007/. Based on November 2009 SEER data submission, posted to the SEER web site.
Bunn PA Jr, Lilenbaum R (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 95(5): 341–343.
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5): 373–383.
Coyte A, Morrison DS, McLoone P (2014) Second primary cancer risk–the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study. BMC cancer 14: 272.
Curtis R, Freedman D, Ron E, Ries L, Hacker D, Edwards B, Tucker M, Fraumeni JJ (2006) New malignancies among cancer survivors: SEER cancer registries 1973–2000 Institute NC (ed) 05-5302. Bethesda, MD: NIH Publ.
de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, Forsythe L, Scoppa S, Hachey M, Rowland JH (2013) Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 22(4): 561–570.
Denicoff AM, McCaskill-Stevens W, Grubbs SS, Bruinooge SS, Comis RL, Devine P, Dilts DM, Duff ME, Ford JG, Joffe S, Schapira L, Weinfurt KP, Michaels M, Raghavan D, Richmond ES, Zon R, Albrecht TL, Bookman MA, Dowlati A, Enos RA, Fouad MN, Good M, Hicks WJ, Loehrer PJ Sr, Lyss AP, Wolff SN, Wujcik DM, Meropol NJ (2013) The national cancer institute-american society of clinical oncology cancer trial accrual symposium: summary and recommendations. J Oncol Pract 9(6): 267–276.
Duchateau CS, Stokkel MP (2005) Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival. Chest 127(4): 1152–1158.
Friedman DR, Dubin N (1991) Case-control evaluation of breast cancer screening efficacy. Am J Epidemiol 133(10): 974–984.
Fu JB, Kau TY, Severson RK, Kalemkerian GP (2005) Lung cancer in women: analysis of the national surveillance, epidemiology, and end results database. Chest 127(3): 768–777.
Fuks A, Weijer C, Freedman B, Shapiro S, Skrutkowska M, Riaz A (1998) A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group. J Clin Epidemiol 51(2): 69–79.
Gerber D, Oxnard G, Govindan R (2015) ALCHEMIST: bringing genomic discovery and targeted therapies to early-stage lung cancer. Clin Pharmacol Ther 97(5): 447–450.
Gerber DE, Laccetti AL, Xuan L, Halm EA, Pruitt SL (2014) Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst 106: 11.
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2(8): 706–714.
Horn L, Keedy VL, Campbell N, Garcia G, Hayes A, Spencer B, Carbone DP, Sandler A, Johnson DH (2013) Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. Clin Lung Cancer 14(1): 14–18.
Iacus SM, King G, Porro G (2011) Multivariate matching methods that are monotonic imbalance bounding. J Am Stat Assoc 106(493): 345–361.
Iacus SM, King G, Porro G (2012) Causal inference without balance checking: coarsened exact matching. Polit Anal 20(1): 1–24.
Johnson C, Peace S, Adamo P, Fritz A, Percy-Laurry A, Edwards B (2014) Multiple primary and histology coding rules manual in the national cancer institute, surveillance. Epidemiology and End Results Program (Revised Edition) 2016. , Bethesda, MD, USA, : National Cancer Institute.
Kim ES, Bernstein D, Hilsenbeck SG, Chung CH, Dicker AP, Ersek JL, Stein S, Khuri FR, Burgess E, Hunt K, Ivy P, Bruinooge SS, Meropol N, Schilsky RL (2015) Modernizing eligibility criteria for molecularly driven trials. J Clin Oncol 33(25): 2815–2820.
Koroukian SM, Dahman B, Copeland G, Bradley CJ (2010) The utility of the state buy-in variable in the Medicare denominator file to identify dually eligible Medicare-Medicaid beneficiaries: a validation study. Health Serv Res 45(1): 265–282.
Kris MG, Meropol NJ, Winer EP (2012) Accelerating Progress Against Cancer: ASCO's Blueprint for Transforming Clinical and Translational Cancer Research.
Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE (2016) Prior cancer does not adversely affect survival in locally advanced lung cancer: a national SEER-medicare analysis. Lung Cancer (Amsterdam, Netherlands) 98: 106–113.
Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE (2015) Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. J Natl Cancer Inst 107(4): pii: djv002.
Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE (2016) Prior cancer does not adversely affect survival in locally advanced lung cancer: a national SEER-medicare analysis. Lung cancer (Amsterdam, Netherlands) 98: 106–113.
Lara PN Jr, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS (2001) Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 19(6): 1728–1733.
Levi F, Randimbison L, Rafael BM, Manuela MC, Vecchia CL (2014) Second primary cancers in the Vaud and Neuchatel Cancer Registries. Eur J Cancer Prev 24: 150–154.
Liu YY, Chen YM, Yen SH, Tsai CM, Perng RP (2002) Multiple primary malignancies involving lung cancer-clinical characteristics and prognosis. Lung Cancer 35(2): 189–194.
Lopez-Encuentra A, Gomez de la Camara A, Rami-Porta R, Duque-Medina JL, de Nicolas JL, Sayas J Bronchogenic Carcinoma Cooperative Group of the Spanish Society of P Thoracic S (2007) Previous tumour as a prognostic factor in stage I non-small cell lung cancer. Thorax 62(5): 386–390.
Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291(22): 2720–2726.
National-Cancer-InstituteSEER-Medicare: Calculation of comorbidity weights (2016) SEER-Medicare Linked Database. National Cancer Institute.
Sagerup CM, Smastuen M, Johannesen TB, Helland A, Brustugun OT (2011) Sex-specific trends in lung cancer incidence and survival: a population study of 40118 cases. Thorax 66(4): 301–307.
Sankila R, Hakulinen T (1998) Survival of patients with colorectal carcinoma: effect of prior breast cancer. J Natl Cancer Inst 90(1): 63–65.
Schootman M, Jeffe DB, Lian M, Aft R, Gillanders WE (2008) Surveillance mammography and the risk of death among elderly breast cancer patients. Breast Cancer Res Treat 111(3): 489–496.
Scoggins JF, Ramsey SD (2010) A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. J Natl Cancer Inst 102(17): 1371.
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1): 5–29.
Tong BC, Kosinski AS, Burfeind WR, Onaitis MW, Berry MF, Harpole DH, D’Amico TA (2014) Sex differences in early outcomes after lung cancer resection: Analysis of the Society of Thoracic Surgeons’ General Thoracic Database. J Thorac Cardiovasc Surg 148(1): 13–18.
Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl):): IV-3-18.
Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML (2008) Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 100(12): 888–897.
Wisnivesky JP, Halm EA (2007) Sex differences in lung cancer survival: do tumors behave differently in elderly women? J Clin Oncol 25(13): 1705–1712.